Skip to main content

Table 4 Overall survival for different patient groups in Study 305/EMBRACE

From: “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

  Progression due to new metastases Progression due to pre-existing lesions No reported disease progression
  Eribulin TPC Total Eribulin TPC Total Eribulin TPC Total
  (n = 139) (n = 68) (N = 207) (n = 189) (n = 73) (N = 262) (n = 180) (n = 113) (N = 293)
Median OS, months (95 % CI) 12.3 (9.9, 13.4) 8.4 (7.0, 14.4) 11.1 (8.9, 13.1) 13.0 (11.1, 14.5) 11.1 (8.7, 15.3) 12.2 (11.0, 14.2) 15.8 (12.1, 19.1) 10.7 (9.2, 14.8) 13.0 (11.1, 16.9)
HR eribulin vs. TPC (95 % CI) 0.76 (0.51, 1.12) 0.74 (0.50, 1.10) 0.77 (0.54, 1.10)
p value 0.16 0.14 0.16
  1. Progression events were determined by independent review
  2. CI confidence interval, EMBRACE Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389, HR hazard ratio, OS overall survival, TPC treatment of physician’s choice